Kondrad, E, Reid, A. Colorado family physicians' attitudes toward medical marijuana. J Am Board Fam Med. 2013;26:52-60.
Booth, M. Cannabis, a history. London, UK: Doubleday; 2003.
Bonnie, RJ, Woodward, CH. The marijuana conviction. Charlottesville (VA): University Press of Virginia; 1974.
Di Marzo, V, Melck, D, Bisogno, T, et al. Endocannabinoids: endogenous cannabinoid receptor ligands with neuromodulatory action. Trends Neurosci. 1998;21:521-528.
Wilson, RI, Nicoll, RA. Endocannabinoid signaling in the brain. Science. 2002;296:678-682.
Pertwee, RG. Pharmacological actions of cannabinoids. Handb Exp Pharmacol. 2005;168:1-51.
Kovacs, FE, Knop, T, Urbanski, MJ, et al. Exogenous and endogenous cannabinoids suppress inhibitory neurotransmission in the human neocortex. Neuropsychopharmacology. 2012;37:1104-1114.
Hoffman, ME, Frazier, CJ. Marijuana, endocannabinoids, and epilepsy: potential and challenges for improved therapeutic intervention. Exp Neurol. 2013;244:43-50.
Hall, W, Solowij, N. Adverse effects of cannabis. Lancet. 1998;352:1611-1616.
Garcia-Merino, A. Endocannabinoid system modulator use in everyday clinical practice in the UK and Spain. Expert Rev Neurother. 2013;13(Suppl 1):9-13.
Serpell, MG, Notcutt, W, Collins, C. Sativex long-term use: an open-label trial in patients with spasticity due to multiple sclerosis. J Neurol. 2013;260:285-295.
Tashkin, DP. Effects of marijuana smoking on the lung. Ann Am Thorac Soc. 2013;10:239-247.
Wang, T, Collet, JP, Shapiro, S, et al. Adverse effects of medical cannabinoids: a systematic review. CMAJ. 2008;178:1669-1678.
Moore, TH, Zammit, S, Lingford-Hughes, A, et al. Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet. 2007;370:319-328.
Minozzi, S, Davoli, M, Bargagli, AM, et al. An overview of systematic reviews on cannabis and psychosis: discussing apparently conflicting results. Drug Alcohol Rev. 2010;29:304-317.
Monte, AA, Bronstein, AC, Cao, DJ, et al. An outbreak of exposure to a novel synthetic cannabinoid. N Engl J Med. 2014;370:389-390.
Anthony, JC, Warner, LA, Kessler, RC. Comparative epidemiology of dependence on tobacco, alcohol, controlled substances, and inhalants: basic findings from the National Comorbidity Survey. Exp Clin Psychopharm. 1994;244-268.
Nutt, D, King, LA, Saulsbury, W, et al. Development of a rational scale to assess the harm of drugs of potential misuse. Lancet. 2007;369:1047-1053.
Pacher, P, Bátkai, S, Kunos, G. The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev. 2006;58:389-462.
Koppel, BS, Brust, JC, Fife, T, et al. Systematic review: efficacy and safety of medical marijuana in selected neurologic disorders: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2014;82:1556-1563.
Gowers, W. Epilepsy and other chronic convulsive disorders. London: Churchill; 1881.
Wada, JA, Osawa, T, Corcoran, ME. Effects of tetrahydrocannabinols on kindled amygdaloid seizures and photogenic seizures in Senegalese baboons, Papio papio. Epilepsia. 1975;16:439-448.
Johnson, DD, McNeill, JR, Crawford, RD, et al. Epileptiform seizures in domestic fowl. The anticonvulsant activity of delta9-tetrahydrocannabinol. Can J Physiol Pharmacol. 1975;53:1007-1013.
Turkanis, SA, Smiley, KA, Borys, HK, et al. An electrophysiological analysis of the anticonvulsant action of cannabidiol on limbic seizures in conscious rats. Epilepsia. 1979;20:351-363.
Meldrum, BS, Fariello, RG, Puil, EA, et al. Delta9-tetrahydrocannabinol and epilepsy in the photosensitive baboon, Papio papio. Epilepsia. 1974;15:255-264.
Martin, P, Consroe, P. Cannabinoid induced behavioral convulsions in rabbits. Science. 1976;194:965-967.
Chiu, P, Olsen, DM, Borys, HK, et al. The influence of cannabidiol and delta 9-tetrahydrocannabinol on cobalt epilepsy in rats. Epilepsia. 1979;20:365-375.
Gloss, D, Vickrey, B. Cannabinoids for epilepsy. Cochrane Database Syst Rev. 2014;(3):CD009270.
Gross, DW, Hamm, J, Ashworth, NL, et al. Marijuana use and epilepsy: prevalence in patients of a tertiary care epilepsy center. Neurology. 2004;62:2095-2097.
McConnell, BV, Applegate, M, Keniston, A, et al. Use of complementary and alternative medicine in an urban county hospital epilepsy clinic. Epilepsy Behav. 2014;34:73-76.
Ladino, LD, Herandez-Ronquillo, L, Tellez-Zenteno, JF. Medical marijuana for epilepsy: a case series. Can J Neurol Sci. 2014;41:753-758.
Porter, BE, Jacobson, C. Report of a parent survey of cannabidiol-enriched cannabis use in pediatric treatment-resistant epilepsy. Epilepsy Behav. 2013;29:574-577.
Aggarwal, SK, Kyashna-Tocha, M, Carter, GT. Dosing medical marijuana: rational guidelines on trial in Washington State. Med Gen Med. 2007;9:52.
Fletcher, J. Marijuana is not a prescription medicine. CMAJ. 2013;185:369.
Devinsky, O, Cilio, MR, Cross, H, et al. Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders. Epilepsia. 2014;55:791-802.